Egetis Therapeutics AB (publ)

OM:EGTX Stock Report

Market Cap: SEK 2.2b

Egetis Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:EGTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Jan 25SellSEK 1,431,249Yilmaz MahshidIndividual213,089SEK 6.82
08 Nov 24BuySEK 25,020Christian SonessonIndividual6,000SEK 4.22
08 Nov 24BuySEK 280,150Henrik KrookIndividual65,000SEK 4.31
07 Oct 24BuySEK 42,250Yilmaz MahshidIndividual10,000SEK 4.23
07 Oct 24BuySEK 43,103Nicklas WesterholmIndividual10,142SEK 4.25

Insider Trading Volume

Insider Buying: EGTX insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of EGTX?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms38,675,50110.8%
Individual Insiders47,846,23913.3%
Private Companies61,976,21117.3%
Institutions65,855,85118.3%
General Public144,884,32440.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.

Top Shareholders

Top 25 shareholders own 59.64% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.8%
Frazier Life Sciences Management, LP
38,675,501SEK 234.0m0%0.85%
9.4%
Cetoros AB
33,776,221SEK 204.3m0%no data
8.35%
Peter Lindell
30,007,682SEK 181.5m0%no data
5.96%
Fourth Swedish National Pension Fund (AP4)
21,404,690SEK 129.5m0%0.05%
4.92%
Avla Holding AB
17,668,330SEK 106.9m0%no data
3.85%
Flerie AB (publ)
13,844,458SEK 83.8m0%12.61%
3.76%
Thomas Eldered
13,499,458SEK 81.7m0%no data
3.29%
Handelsbanken Asset Management
11,831,897SEK 71.6m0%0.01%
2.93%
Recipharm AB (publ)
10,531,660SEK 63.7m0%no data
2.1%
Linc AB
7,532,021SEK 45.6m0%2.44%
1.93%
Unionen, Endowment Arm
6,946,793SEK 42.0m0%1.14%
0.87%
Mats Blom
3,134,762SEK 19.0m0%no data
0.47%
SEB Investment Management AB
1,682,563SEK 10.2m10.7%no data
0.28%
Swedbank Robur Fonder AB
1,000,000SEK 6.1m0%no data
0.21%
FCG Fonder AB
772,249SEK 4.7m0%0.05%
0.11%
Henrik Krook
404,593SEK 2.4m19.1%no data
0.086%
Financiere Arbevel
310,000SEK 1.9m0%0.04%
0.079%
Thomas Lonngren
283,158SEK 1.7m0%no data
0.07%
Avanza Fonder AB
250,662SEK 1.5m0%no data
0.068%
Nicklas Westerholm
242,718SEK 1.5m4.36%no data
0.049%
Skandia Fonder AB
176,659SEK 1.1m0%no data
0.028%
Yilmaz Mahshid
100,000SEK 605.1k-67%no data
0.021%
Storebrand Fonder AB,
73,895SEK 447.1k0%no data
0.012%
Christian Sonesson
42,298SEK 255.8k16.5%no data
0.011%
Gunilla Osswald
40,000SEK 241.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 11:40
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Patrick LangstromABG Sundal Collier Sponsored
Oscar Haffen LammBryan Garnier & Co